MACSF

COMMUNIQUÉS West-GlobeNewswire

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
09/07/2025
Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as Chief Medical Officer; Dr. Daniel Adelman to serve as Acting Chief Medical Officer [...]
Dr. Anosh Ahmed Plans $25,000 Donation to Support FBI Families and Law Enforcement Mental Health Programs
09/07/2025
Chicago-based physician to contribute through Anosh Inc Foundation and host local fundraiser in support of federal agents Image by Dr. Anosh Ahmed CHICAGO, July 09, 2025 (GLOBE NEWSWIRE) -- Dr. Anosh Ahmed, a Chicago- [...]
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates
09/07/2025
Custom-built model will be trained using Revolution Medicines’ proprietary data to discover novel drug candidates Iambic to receive up to $25 million through a combination of upfront and expected near-term performance- [...]
The Anosh Foundation Launches Global Oversight Initiative to Strengthen COVID-19 Testing and Vaccination Integrity
09/07/2025
Nonprofit organization enhances international COVID response efforts with new compliance and quality assurance measures. Image of Dr. Anosh Ahmed CHICAGO, July 09, 2025 (GLOBE NEWSWIRE) -- The Anosh Foundation , led by [...]
New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials
09/07/2025
Article Indicates that Inhibition of PP2A Enhances Immunotherapy Response with LIXTE’s Proprietary Compound LB100 PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “ [...]
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
09/07/2025
ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
09/07/2025
NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036
09/07/2025
Extends patent exclusivity period an additional 6 years once granted SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on [...]
Vireo Growth Inc. Announces Retirement of November 2024 Convertible Note
09/07/2025
-- Company concurrently refinances convertible note on amended terms in conjunction with larger refinancing -- MINNEAPOLIS, July 09, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; [...]
FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank
09/07/2025
HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of [...]
THC Therapeutics, Inc. Announces Acquisition of SugarTop Buddery
09/07/2025
Ten-Year Legacy Brand Joins THCT Portfolio, Expanding National Craft Cannabis Footprint and Female-Founded Leadership MEDFORD, Ore., July 09, 2025 (GLOBE NEWSWIRE) -- THC Therapeutics, Inc. (“THCT” or the “Company”), ( [...]
Clover Health Launches New Jersey Community Pharmacy Program in Partnership with IPC’s iCare+ Network
09/07/2025
WILMINGTON, Del., July 09, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”) , a leading Medicare Advantage company committed to affordable, high-quality care, today announced [...]
Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies
09/07/2025
Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year Company continues to advance its contemplated merger with Decoy Therapeutics HOUSTON, [...]
Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements
09/07/2025
CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has [...]
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
09/07/2025
Tegoprubart to be Used as Immunosuppressive Agent in Cohort C of Sernova’s Phase 1/2 Cell Pouch Bio-hybrid Organ Clinical Trial in Patients with Type 1 Diabetes LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova [...]
Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law
09/07/2025
Fountain Life operates four flagship longevity centers, including two in Florida, where a new state law effective July 1, 2025, authorizes licensed physicians to administer stem cell therapies to members with conditions [...]
Helius Medical Technologies, Inc. Compliant with Nasdaq’s Continued Listing Requirements
09/07/2025
NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for [...]
Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045
09/07/2025
Application Update Based on Extensive Review of Data GLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company [...]
Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines
09/07/2025
Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery System; Company is Currently Conducting Additional Studies into New and Previously Untested KRAS [...]

Pages